SIRT1 expression is associated with good prognosis in colorectal cancer

Korean Journal of Pathology

Volumn 47, Issue 4, 2013, Pages 332-339

  Jung, Wonkyung ^a   Hong, Kwang Dae ^a   Jung, Woon Yong ^a   Lee, Eunjung ^a   Shin, Bong Kyung ^a   Kim, Han Kyeom ^a   Kim, Aeree ^a   Kim, Baek Hui ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Beta catenin.; Colon; Dbc1; Sirt1

Indexed keywords

EID: 84884563591     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2013.47.4.332     Document Type: Article

References (28)

1. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 2004; 16: 93-105.
2. Haigis MC, Guarente LP. Mammalian sirtuins: emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006; 20: 2913-21.
3. Stünkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007; 2: 1360-8.
4. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A 2005; 102: 1859-64.
5. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-48.
6. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 2008; 3: e2020.
7. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol Cell 2008; 32: 11-20.
8. Jang SH, Min KW, Paik SS, Jang KS. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol 2012; 65: 735-9.
9. Nosho K, Shima K, Irahara N, et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol 2009; 22: 922-32.
10. Kabra N, Li Z, Chen L, et al. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem 2009; 284: 18210-7.
11. Kang Y, Jung WY, Lee H, Lee E, Kim A, Kim BH. Expression of SIRT1 and DBC1 in Gastric Adenocarcinoma. Korean J Pathol 2012; 46: 523-31.
12. Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009; 15: 4453-9.
13. Hamaguchi M, Meth JL, von Klitzing C, et al. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci U S A 2002; 99: 13647-52.
14. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008; 451: 583-6.
15. Lee H, Kim KR, Noh SJ, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011; 42: 204-13.
16. Zhang Y, Gu Y, Sha S, et al. DBC1 is over-expressed and associated with poor prognosis in colorectal cancer. Int J Clin Oncol 2013 Jan 9 [Epub]. http://dx.doi.org/10.1007/s10147-012-0506-5.
17. Czyzewska J, Guzinska-Ustymowicz K, Ustymowicz M, Pryczynicz A, Kemona A. The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis. Folia Histochem Cytobiol 2010; 48: 37-45.
18. Salim T, Sjölander A, Sand-Dejmek J. Nuclear expression of glycogen synthase kinase-3beta and lack of membranous beta-catenin is correlated with poor survival in colon cancer. Int J Cancer 2013; 133: 807-15.
19. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798-812.
20. Mirza A, McGuirk M, Hockenberry TN, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
21. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press, 2010.
22. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
23. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241-50.
24. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
25. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-84.
26. Chen L, Liang L, Yan X, et al. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer 2013; 23: 256-63.
27. Meng JR, Tang HZ, Zhou KZ, Shen WH, Guo HY. TFF3 and survivin expressions associate with a lower survival rate in gastric cancer. Clin Exp Med 2012 Sep 21 [Epub]. http://dx.doi.org/10.1007/s10238-012-0210-9.
28. Qi G, Tuncel H, Aoki E, et al. Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 2009; 22: 557-62.